April 28, 2014 08:30 ET JC: To date, we have scre

Quote:

---

April 28, 2014 08:30 ET
JC: To date, we have screened 37 of our library of 88 astrocyte cell lines. All 37 ACMs screened to date secrete neuroprotective molecules, and several meet the criteria for further analysis as potential drug candidates for PD. We are beginning to analyze the effects of different ACM on the six sub-types of dopaminergic neurons present in the nigral cell culture and in vivo. One ACM protected 3 of the 6 subtypes, while another protected only one. It is unknown if selective death of dopaminergic subtypes occurs in different Parkinsonian brains. If yes, these preliminary results could have important implications for the way in which future clinical trials of neurotrophic factors for Parkinson's disease are conducted.

---

Quote:

---

GC: "We are pleased to re-engage with the research community regarding our PhenoGuard discovery platform, now that MANF has achieved proof of concept across a number of therapeutic indications, and is on a path for first-in-man studies in retinal disorders and Parkinson's disease," said Gerald C. Commissiong, President & CEO of Amarantus. "We believe the discovery of a second family of neurotrophic factors would represent a sea-change in the research community and further validate the uniqueness and value of our technology."

---